GlassScriptPhysician profile
Michelle Whittaker
NPI 1841721891
$4,507.07
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,871 · 2022: $1,919 · 2023: $697 · 2024: $20.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $717.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $717.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $700.46 | 2021-2023 | |
| Lundbeck LLC | $486.94 | 2021-2023 | Abilify Maintena, Rexulti |
| Sunovion Pharmaceuticals INC. | $420.47 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $385.92 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $355.86 | 2021-2023 | Trintellix |
| Supernus Pharmaceuticals, INC. | $348.35 | 2021-2023 | Qelbree |
| Avanir Pharmaceuticals, INC. | $292.29 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $254.22 | 2021-2023 | Nuedexta |
| Alkermes, INC. | $253.43 | 2021-2023 | Lybalvi, Vivitrol |
| Janssen Pharmaceuticals, INC | $241.64 | 2021-2023 | Invega Trinza, Invega Sustenna, Invega |
| Axsome Therapeutics, INC. | $123.87 | 2023 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $116.10 | 2021-2022 | |
| Bausch Health US, LLC | $89.64 | 2021-2022 | |
| Corium, LLC | $81.64 | 2022-2023 | Azstarys |
| Neurocrine Biosciences, INC. | $80.50 | 2022-2023 | Ingrezza |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $72.59 | 2022-2023 | Belsomra |
| Vanda Pharmaceuticals INC. | $65.81 | 2021 | |
| Idorsia Pharmaceuticals US INC | $38.03 | 2022 | |
| Eisai INC. | $36.07 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $23.46 | 2022 | |
| Braeburn INC. | $20.14 | 2024 | Brixadi |
| Indivior INC. | $19.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Whittaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.